BioSpace News Archive

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today provided a corporate update and reported financial results for the first quarter 2023.

Candel Therapeutics, Inc today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will deliver an oral presentation at the European Congress of Endocrinology (ECE) 2023 Annual Meeting, which is being held May 13-16 in Istanbul, Turkey.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended March 31, 2023 and provided a business update.

ReWalk Robotics Ltd. today announced its financial results for the three months ended March 31, 2023.

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023.

Avalyn Pharma Inc. today announced that the company will be participating in the upcoming American Thoracic Society (ATS) annual meeting and its associated Respiratory Innovation Summit (RIS), which are being held at the Marriott Marquis in Washington, DC.

Providence Medical Technology, Inc. (PMT) today announced the close of enrollment in its FUSE Study — a prospective, multicenter, randomized, Investigational Device Exemption (IDE) clinical study evaluating the safety and effectiveness of its Posterior Cervical Stabilization System (PCSS) in 3-level cervical fusion patients.